Cargando…

Design and methodology of the PRIMETIME 1 cohort study: PRecIsion MEdicine based on kidney TIssue Molecular interrogation in diabetic nEphropathy

BACKGROUND: Clinical features of diabetic kidney disease alone cannot differentiate between the histopathology that defines diabetic nephropathy (DN) and non-diabetic nephropathy (NDN). A kidney biopsy is necessary to make the definitive diagnosis of DN. However, there is no consensus on when to per...

Descripción completa

Detalles Bibliográficos
Autores principales: Jensen, Karina Haar, Persson, Frederik, Hansen, Ditte, Bressendorff, Iain, Møller, Marie, Rossing, Peter, Gravesen, Eva, Kosjerina, Vanja, Vistisen, Dorte, Borg, Rikke
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10689178/
https://www.ncbi.nlm.nih.gov/pubmed/38046022
http://dx.doi.org/10.1093/ckj/sfad150
_version_ 1785152317307224064
author Jensen, Karina Haar
Persson, Frederik
Hansen, Ditte
Bressendorff, Iain
Møller, Marie
Rossing, Peter
Gravesen, Eva
Kosjerina, Vanja
Vistisen, Dorte
Borg, Rikke
author_facet Jensen, Karina Haar
Persson, Frederik
Hansen, Ditte
Bressendorff, Iain
Møller, Marie
Rossing, Peter
Gravesen, Eva
Kosjerina, Vanja
Vistisen, Dorte
Borg, Rikke
author_sort Jensen, Karina Haar
collection PubMed
description BACKGROUND: Clinical features of diabetic kidney disease alone cannot differentiate between the histopathology that defines diabetic nephropathy (DN) and non-diabetic nephropathy (NDN). A kidney biopsy is necessary to make the definitive diagnosis of DN. However, there is no consensus on when to perform a kidney biopsy in individuals with diabetes and kidney disease. Furthermore, the implications of NDN versus DN for management, morbidity and kidney prognosis are unclear. To address the gap in knowledge, we aimed to create a national retrospective cohort of people with diabetes and a performed kidney biopsy. METHODS: Adults diagnosed with diabetes in Denmark between 1996 and 2020 who had a kidney biopsy performed were included. The cohort was established by linking a nationwide diabetes registry with the Danish Pathology Registry. Data from 11 national registries and databases were compiled. The type of kidney disease was classified using a three-step analysis of Systematized Nomenclature of Medicine codes reported in relation to the histopathological examinations of kidney tissue. The final cohort and classification of kidney disease was as follows: out of 485 989 individuals with diabetes 2586 were included, 2259 of whom had type 2 diabetes. We were able to classify 599 (26.5%) with DN, 703 (31.1%) with NDN and 165 (7.3%) with mixed disease in individuals with type 2 diabetes. In individuals with type 1 diabetes, 132 (40.4%) had DN, 73 (22.3%) NDN and 39 (11.9%) mixed disease. The remaining could not be classified or had normal histology. The overall median (Q1–Q3) follow-up time was 3.8 (1.6–7.2) years. CONCLUSIONS: This cohort is a novel platform based on high-quality registry data for important longitudinal studies of the impact of kidney disease diagnosis on prognosis. With regular updates of data from the Danish registries, the presented follow-up will increase over time and is only limited by emigration or death.
format Online
Article
Text
id pubmed-10689178
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-106891782023-12-02 Design and methodology of the PRIMETIME 1 cohort study: PRecIsion MEdicine based on kidney TIssue Molecular interrogation in diabetic nEphropathy Jensen, Karina Haar Persson, Frederik Hansen, Ditte Bressendorff, Iain Møller, Marie Rossing, Peter Gravesen, Eva Kosjerina, Vanja Vistisen, Dorte Borg, Rikke Clin Kidney J Original Article BACKGROUND: Clinical features of diabetic kidney disease alone cannot differentiate between the histopathology that defines diabetic nephropathy (DN) and non-diabetic nephropathy (NDN). A kidney biopsy is necessary to make the definitive diagnosis of DN. However, there is no consensus on when to perform a kidney biopsy in individuals with diabetes and kidney disease. Furthermore, the implications of NDN versus DN for management, morbidity and kidney prognosis are unclear. To address the gap in knowledge, we aimed to create a national retrospective cohort of people with diabetes and a performed kidney biopsy. METHODS: Adults diagnosed with diabetes in Denmark between 1996 and 2020 who had a kidney biopsy performed were included. The cohort was established by linking a nationwide diabetes registry with the Danish Pathology Registry. Data from 11 national registries and databases were compiled. The type of kidney disease was classified using a three-step analysis of Systematized Nomenclature of Medicine codes reported in relation to the histopathological examinations of kidney tissue. The final cohort and classification of kidney disease was as follows: out of 485 989 individuals with diabetes 2586 were included, 2259 of whom had type 2 diabetes. We were able to classify 599 (26.5%) with DN, 703 (31.1%) with NDN and 165 (7.3%) with mixed disease in individuals with type 2 diabetes. In individuals with type 1 diabetes, 132 (40.4%) had DN, 73 (22.3%) NDN and 39 (11.9%) mixed disease. The remaining could not be classified or had normal histology. The overall median (Q1–Q3) follow-up time was 3.8 (1.6–7.2) years. CONCLUSIONS: This cohort is a novel platform based on high-quality registry data for important longitudinal studies of the impact of kidney disease diagnosis on prognosis. With regular updates of data from the Danish registries, the presented follow-up will increase over time and is only limited by emigration or death. Oxford University Press 2023-06-24 /pmc/articles/PMC10689178/ /pubmed/38046022 http://dx.doi.org/10.1093/ckj/sfad150 Text en © The Author(s) 2023. Published by Oxford University Press on behalf of the ERA. https://creativecommons.org/licenses/by-nc/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial License (https://creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com
spellingShingle Original Article
Jensen, Karina Haar
Persson, Frederik
Hansen, Ditte
Bressendorff, Iain
Møller, Marie
Rossing, Peter
Gravesen, Eva
Kosjerina, Vanja
Vistisen, Dorte
Borg, Rikke
Design and methodology of the PRIMETIME 1 cohort study: PRecIsion MEdicine based on kidney TIssue Molecular interrogation in diabetic nEphropathy
title Design and methodology of the PRIMETIME 1 cohort study: PRecIsion MEdicine based on kidney TIssue Molecular interrogation in diabetic nEphropathy
title_full Design and methodology of the PRIMETIME 1 cohort study: PRecIsion MEdicine based on kidney TIssue Molecular interrogation in diabetic nEphropathy
title_fullStr Design and methodology of the PRIMETIME 1 cohort study: PRecIsion MEdicine based on kidney TIssue Molecular interrogation in diabetic nEphropathy
title_full_unstemmed Design and methodology of the PRIMETIME 1 cohort study: PRecIsion MEdicine based on kidney TIssue Molecular interrogation in diabetic nEphropathy
title_short Design and methodology of the PRIMETIME 1 cohort study: PRecIsion MEdicine based on kidney TIssue Molecular interrogation in diabetic nEphropathy
title_sort design and methodology of the primetime 1 cohort study: precision medicine based on kidney tissue molecular interrogation in diabetic nephropathy
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10689178/
https://www.ncbi.nlm.nih.gov/pubmed/38046022
http://dx.doi.org/10.1093/ckj/sfad150
work_keys_str_mv AT jensenkarinahaar designandmethodologyoftheprimetime1cohortstudyprecisionmedicinebasedonkidneytissuemolecularinterrogationindiabeticnephropathy
AT perssonfrederik designandmethodologyoftheprimetime1cohortstudyprecisionmedicinebasedonkidneytissuemolecularinterrogationindiabeticnephropathy
AT hansenditte designandmethodologyoftheprimetime1cohortstudyprecisionmedicinebasedonkidneytissuemolecularinterrogationindiabeticnephropathy
AT bressendorffiain designandmethodologyoftheprimetime1cohortstudyprecisionmedicinebasedonkidneytissuemolecularinterrogationindiabeticnephropathy
AT møllermarie designandmethodologyoftheprimetime1cohortstudyprecisionmedicinebasedonkidneytissuemolecularinterrogationindiabeticnephropathy
AT rossingpeter designandmethodologyoftheprimetime1cohortstudyprecisionmedicinebasedonkidneytissuemolecularinterrogationindiabeticnephropathy
AT graveseneva designandmethodologyoftheprimetime1cohortstudyprecisionmedicinebasedonkidneytissuemolecularinterrogationindiabeticnephropathy
AT kosjerinavanja designandmethodologyoftheprimetime1cohortstudyprecisionmedicinebasedonkidneytissuemolecularinterrogationindiabeticnephropathy
AT vistisendorte designandmethodologyoftheprimetime1cohortstudyprecisionmedicinebasedonkidneytissuemolecularinterrogationindiabeticnephropathy
AT borgrikke designandmethodologyoftheprimetime1cohortstudyprecisionmedicinebasedonkidneytissuemolecularinterrogationindiabeticnephropathy